Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

Bradley J Monk; Thomas J Herzog; George Wang; Spyros Triantos; Scott Maul; Roland Knoblauch; Tracy McGowan; Waleed S W Shalaby; Robert L Coleman

doi:10.1016/j.dib.2020.105465

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

Data Brief. 2020 Mar 20:30:105465. doi: 10.1016/j.dib.2020.105465. eCollection 2020 Jun.

Authors

Bradley J Monk¹, Thomas J Herzog², George Wang³, Spyros Triantos³, Scott Maul⁴, Roland Knoblauch³, Tracy McGowan⁵, Waleed S W Shalaby⁵, Robert L Coleman⁶

Affiliations

¹ Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, United States.
² University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, OH, United States.
³ Janssen Research & Development, Spring House, PA, United States.
⁴ Janssen Research & Development, Los Angeles, CA, United States.
⁵ Janssen Scientific Affairs, LLC, Horsham, PA, United States.
⁶ The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Abstract

The data presented herein are supplementary to our published primary article "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups.

Keywords: Overall survival; Pegylated liposomal doxorubicin; Recurrent ovarian cancer; Response rate; Trabectedin.